ERBB2 and gastric cancer: In this light, our findings open a new research line: if proven that ErbB2 is, in fact, an in vivo protein carrier of SLea in ErbB2-positive GC patients, assessing ErbB2 modified with SLea in the sera of patients might surpass the clinical performance of either circulating ErbB2 or SLea.